Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Myelofibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
DE-Aachen-UKAACHEN, Aachen, Germany
Contact: Study coordinator (Martine Chrysandt, Dr.)NL-Amsterdam-AmsterdamUMC, Amsterdam, Netherlands
NL-Groningen-UMCG, Groningen, Netherlands
NL-Nijmegen-RADBOUDUMC, Nijmegen, Netherlands
NL-Rotterdam-ERASMUSMC, Rotterdam, Netherlands
NL-Utrecht-UMCUTRECHT, Utrecht, Netherlands
Study leads
Peter te Boekhorst, Dr.
Principal Investigator
Erasmus Medical Center